Karyopharm Therapeutics Inc. - 8-K Filing

Karyopharm Therapeutics submitted an sNDA for XPOVIO in combination with ruxolitinib for myelofibrosis seeking Accelerated Approval (Items: 8.01 Other Events)

SEC EDGAR ·

Tickers: $KPTI

Read the full article at SEC EDGAR

More Regulatory news